No profile data available.
Bausch + Lomb Corporation (BLCO) is a healthcare company in the eye treatment pharmaceuticals industry, based in Vaughan, Canada, with about 13,000 full-time employees.
It reported revenue of $5.10 billion for fiscal year 2025, up 6.5% from fiscal year 2024, and net income of -$360.00 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.39 billion, up 9.1% from a year before. Its largest business segment, Vision Care, brought in 57% of segment revenue in fiscal year 2025; U.S. and Puerto Rico was the largest region with 50%. Its market capitalization was $6.18 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Bausch + Lomb reported $5.10 billion in revenue for fiscal year 2025, up 6.5% from $4.79 billion in fiscal year 2024. In Q2 2026 revenue was $1.39 billion.
Vision Care, with $2.92 billion or 57% of segment revenue in fiscal year 2025. Next: Pharmaceuticals (25%) and Surgical (18%).
U.S. and Puerto Rico: 50% of revenue by region in fiscal year 2025, followed by Other (15%).
$6.18 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Regeneron Pharmaceuticals, Inc. (REGN), Kodiak Sciences Inc. (KOD), Belite Bio, Inc (BLTE), MeiraGTx Holdings plc (MGTX).